



RECEIVED


#1

APR 19 2001

TECH CENTER 1600/2900

1493-131 US

The undersigned certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on April 12, 2001.



Valerie Balfour

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Perritti, M., et al.

Serial No. 09/759,484

Filed: January 12, 2001

For: ANTI-INFLAMMATORY
COMPOUNDS

Group Art Unit: 1614
Examiner: TBA

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references **A** through **H** listed on the attached PTO form 1449. Photocopies of the cited references are submitted herewith.



Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.


Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is submitted that no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Mathews, Collins, Shepherd & Gould, P.A. Deposit Account No. 13-2165; a duplicate of this sheet is enclosed.

TECH CENTER 1600/2900
APR 19 2001


RECEIVED

Date: April 12, 2001

Respectfully submitted,

Bruce M. Collins
Reg. No. 20,066

Mathews, Collins, Shepherd & Gould, P.A.
100 Thanet Circle, Suite 306
Princeton, New Jersey 08540

Phone (609) 924-8555
Fax (609) 924-3036



RECEIVED

APR 19 2001

TECH CENTER 1600/2900

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Sheet 1 of 2

Docket No.1493-131 US

Serial No. 09/759,484

Applicant: Perretti, M. et al.
Filing Date: 01/12/01 **Group: 1614**

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS



RECEIVED  RECEIVED

APR 19 2001

MAY 10 2001

RM PTO-1449

INFORMATION DISCLOSURE CITATION

TECH CENTER 1600/2900 TECH CENTER 1600/2900 Sheet 2 of 2
Docket No. I493-131 US
Serial No. 09/759,484
Applicant: Perritti, M. et. al.
Filing Date: 01/12/01 Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	B	L.H. Lim et al., Promoting detachment of neutrophils adherent to murine postcapillary venules to control inflammation: Effect of lipocortin1, <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95(24), 14535-9
	C	J.D. Croxtall et al., N-Terminal Peptide Fragments of Lipocortin-1 Inhibit A549 Cell Growth and Block EGF-Induced Stimulation of Proliferation, <i>International Journal of Cancer</i> , 1993, 54(1), 153-8
	D	M. Perretti et al., Lipocortin-1 Fragments Inhibit Neutrophil Accumulation and Neutrophil-Dependent Edema in the Mouse, <i>Journal of Immunology</i> , 1993, 151(8), 4306-14
	E	Croxtall et al., Inhibitory effect of peptides derived from the N-terminus of lipocortin 1 on arachidonic acid release and proliferation in the A549 cell line: identification of E-Q-E-Y-V as a crucial component, <i>British Journal of Pharmacology</i> , 1998, 123, 975-983
	F	<i>Oxford Dictionary of Biochemistry and Molecular Biology</i> , Oxford University Press 1997, pp. 537-538
.	G	I.T. Paulsen et al., Characterisation of <i>sin</i> , a potential recombinase-encoding gene from <i>Staphylococcus aureus</i> , <i>Gene</i> , 1994, 141, 109-114
	H	P. Dezelee et al., Small Deletion in <i>v-src</i> SH3 Domain of a Transformation Defective Mutant of Rous Sarcoma Virus Restores Wild Type Transforming Properties, <i>Virology</i> , 1992, 189, 556-567
EXAMINER	DATE CONSIDERED	

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please place a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0041
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED
PTO-1449 (02-00)

MAY 10 2001

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/759,484
		Filing Date	01/12/01
		First Named Inventor	Perritti, M. et al.
		Group Art Unit	1614
		Examiner Name	TBA
Total Number of Pages in This Submission	101	Attorney Docket Number	1493-119.1 US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Reference Documents as delineated on the PTO-1449 form
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Remarks
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

APR 19 2001

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Bruce M. Collins
Signature	
Date	04/12/01

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	Valerie Balfour	
Signature		Date
		04/12/01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.